Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Small Cell Lung Carcinoma 1Sarcoma 1Parathyroid Neoplasms 1Neuroendocrine Tumors 1Melanoma 1Carcinoid Tumor 1

Interventions

Cisplatin 4atezolizumab 2Topotecan 2Paclitaxel 2Nivolumab 2Etoposide 2veliparib 1tocilizumab 1tislelizumab 1temsirolimus 1surufatinib 1sargramostim 1pentetreotide 1pembrolizumab 1niraparib 1iadademstat 1entinostat 1durvalumab 1dostarlimab 1cabozantinib 1budigalimab 1berzosertib 1belinostat 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1Sirolimus 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × Dacarbazine × Endocrine × Clear all
NCT00580320 2016-08-18

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Virginia Commonwealth University

Phase 1 Completed
17 enrolled
DermatologicEndocrineHead & NeckSarcomaThoracic

Carcinoid Tumor, Melanoma, Parathyroid Neoplasms, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡